Key facts
- It has raised $18.3M; the latest was Later Stage VC ($18.3M) in Nov 2025.
- Notable investors include Qiming Venture Partners, Tailong VC, HaiBang Ventures, Heda Ventures, StepVC — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Hezheng Pharmaceutical
- ·The full record, as it builds
Funding rounds
No funding rounds for Hezheng Pharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Hezheng Pharmaceutical
Developer of innovative and generic drug formulations and synthetic processes intended for therapeutic research. The company offers integrated capabilities in novel drug discovery, formulation development, and process optimization, thereby enabling pharmaceutical manufacturers and healthcare providers to access high-quality, research-driven products that meet scalability across diverse therapeutic areas.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2012
- Website
- cn.healzentx.com/
- Ownership
- Privately Held (backing)
Hezheng Pharmaceutical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hezheng Pharmaceutical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hezheng Pharmaceutical in its N-PORT filings yet. We sweep new filings monthly.